HTA ID Drug Brand Indication Assessment status Date
24006 Quizartinib Vanflyta® Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia that is FLT3-ITD positive. Rapid Review Complete 11th March 2024